Nouscom
Bäumleingasse 18
Basel
CH-4051
Tel: 41-61-201-18-3
Website: http://www.nouscom.com/
Email: info@nouscom.com
About Nouscom
Nouscom is a private oncology company developing next generation immunotherapies. Nouscom's proprietary technology platform harnesses the full power of immune response by combining oncolytic viruses specifically targeted to a tumor with viral vectored genetic vaccines based on patient specific neo-antigens.YEAR FOUNDED:
2015
LEADERSHIP:
Co-Founder and CEO of HQ: Riccardo Cortese, PhD, MD
Co-Founder and CEO of Italy: Alfredo Nicosia, PhD
Co-Founder and CSO: Elisa Scarselli, MD
Co-Founder and CTO: Stefano Colloca, MD
Co-Founder and Head of Immunology: Antonella Folgori, PhD
Co-Founder and Senior Director of Regulatory Affairs: Cinzia Traboni, PhD
COO: Marina Udier, PhD
SCIENCE:
Please click here for Nouscom's science.
16 articles with Nouscom
-
Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy
3/15/2023
Nouscom announced that new translational data obtained from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma has been accepted for presentation in a Late-Breaking session at the 2023 American Association for Cancer Research Annual Meeting.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
BioSpace Movers & Shakers, Feb. 28
2/28/2020
Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers & Shakers. -
BioSpace Global Roundup, Dec. 12
12/12/2019
Companies from across the globe provide updates to their business and pipelines. -
BioSpace Global Roundup, June 6
6/6/2019
Companies from across the globe share updates on their pipelines and growth strategies. -
Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director
11/5/2018
Nouscom announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.
-
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
-
NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model
11/13/2017
Nouscom, an oncology company developing next generation cancer vaccines based on its Exovax platform, today announced preclinical data of its neoantigen-based cancer vaccine in combination with Nektar Therapeutics' NKTR-214, a CD122-biased cytokine agonist which is currently in clinical trials.
-
The round was led by new investor Abingworth with participation from another new investor, 5AM Ventures, LSP and Versant Ventures.
-
Nouscom Appoints New Chief Operating Officer And Strengthens The Board Of Directors
9/26/2016